Peregrine Pharmaceuticals begins dosing in Phase II trial of bavituximab
The new trial is the second Phase II study evaluating bavituximab in advanced breast cancer patients, and Peregrine also is conducting a third Phase II combination therapy trial
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.